^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Glioma |
| Drug: | Delytact (teserpaturev) (Apoptosis stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DELYTACT® Oncolytic Virus G47? Approved in Japan for Treatment of Patients with Malignant Glioma
Published date:
06/11/2021
Excerpt:
…Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for DELYTACT® (teserpaturev/G47∆), an oncolytic virus, for the treatment of patients with malignant glioma.
